Malaria and helminth parasite infections are the most prevalent diseases in tropical and subtropical regions . Medicines such as albendazole (ABZ) and praziquantel (PZQ) and fixed dose combination of artemether (ART)/lumefantrine (LUM) are recommended by World Health Organization (WHO) to treat helminth parasite infections and malaria caused by Plasmodium falciparum, respectively. However, bio-relevant validated dissolution conditions used for in-vitro dissolution test of these drugs are currently missing. In developing countries where there is poor chain of pharmaceutical regulatory system, poor quality medicines could enter into legal pharmaceutical supply chain and reach the patients . For solid oral dosage forms, like tablets, disintegration of the powder mixture and dissolution of the active pharmaceutical ingredient (API) in the gastrointestinal medium is very critical for systemic and/or local absorption. Since poor dissolution could affect concentration of API at the target site which in turn influence clinical efficacy, verifying the dissolution of medicines using bio-relevant and discriminatory dissolution condition is important. Thus, developing bio-relevant and discriminatory dissolution conditions which could be utilized for quality control and prediction of in-vivo performance for a selected set of neglected tropical disease medicines is critical. Therefore, the PhD project focuses on the development of bio-relevant dissolution conditions for neglected tropical disease medicines.